Browse
Search
Agenda - 01-23-2018 4-b - Presentation on Opioids and Legal Issues
OrangeCountyNC
>
Board of County Commissioners
>
BOCC Agendas
>
2010's
>
2018
>
Agenda - 01-23-2018
>
Agenda - 01-23-2018 4-b - Presentation on Opioids and Legal Issues
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
1/22/2018 10:49:04 AM
Creation date
1/22/2018 8:39:31 AM
Metadata
Fields
Template:
BOCC
Date
1/23/2018
Meeting Type
Regular Meeting
Document Type
Agenda
Agenda Item
4-b
Document Relationships
Agenda - 01-23-2018 - Regular Meeting Agenda
(Message)
Path:
\Board of County Commissioners\BOCC Agendas\2010's\2018\Agenda - 01-23-2018
Minutes 01-23-2018
(Message)
Path:
\Board of County Commissioners\Minutes - Approved\2010's\2018
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
24
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
9 <br />distributors admit that they "are uniquely situated to perform duee diligence in order to help <br />support the security" of controlled substance distribution.3 <br />The Guidelines set out "Know Your Customer Due Diligence" standards with respect to <br />all distributor customers — which, in the context of the Guidelines, comprises pharmacies and <br />other legal dispensaries. These due diligence standards include gathering detailed information on <br />the customer base of a pharmacy, the quantity of prescriptions filled each day, the quantity of <br />controlled substance prescriptions filled each day, and the percentage of controlled substance <br />purchases compared to overall purchases, and then utilizing this information to compare orders <br />to a "threshold" profile to identify orders of unusual size, frequency or pattern. When confronted <br />with "unusual" orders, the distributors' own Guidelines dictate that they should stop the <br />shipments, investigate the orders under steps that are listed in the Guidelines, and report the <br />suspicious activity to the DEA. These industry standards clearly establish that the duty of care <br />for pharmaceutical distributors includes identifying, investigating, and reporting suspicious <br />orders of controlled substances. <br />Distributors have chosen to abandon their duties, thereby enabling the diversion of <br />opioids and helping to create the present epidemic. The distributors have not performed adequate <br />due diligence and have failed to report suspicious orders, breaching the very industry standards <br />they, themselves, created. In doing so, the distributors have violated their duties of care and both <br />federal and North Carolina state law. <br />D. "ARCOS" Data Contains Key Evidence of the Distributors' Breaches. <br />One of the ways wholesale distributors are to maintain controls against the diversion of <br />prescription opiates is by inputting all distributions in the DEA Automation of Reports and <br />3 See HDMA Industry Compliance Guidelines. <br />North Carolina County Opioid Litigation - Privileged and Confidential 6 <br />
The URL can be used to link to this page
Your browser does not support the video tag.